A small molecule inhibits pancreatic cancer stem cells Article

Das, JK, Das, M, Doke, M et al. (2021). A small molecule inhibits pancreatic cancer stem cells . 26 1-15. 10.52756/ijerr.2021.v26.001

cited authors

  • Das, JK; Das, M; Doke, M; Wnuk, S; Stiffin, RM; Ruiz, M; Celli, JP

authors

abstract

  • Pancreatic cancer is the fourth highest cause of cancer-related deaths in the United States, with a projected 60,430 new cases diagnosed and 48,220 patients dying in 2021. We employed a small chemical, N-(6-Chloro-2-enzothiazolyl)-3, 4-dimethoxy-benzene propanamide (KY-02111), to target suppression of tumori-sphero-genesis of PANC1ORGRCD19+31+45+133+, to propose a novel therapeutic strategy against drug registrant pancreatic cancer stem cells (PANC1ORGRCD19+31+45+133+). According to our findings, the pancreatic stem cell indicators (CD19+31+45+133+) are found to be more strongly expressed in pancreatic cancer tissues than in normal pancreatic tissues.The flow cytometry, immunoblot and immunofluorescence analysis showed that the expression ofthese markers (CD19+31+45+133+) in PANC1ORGR spheroid cells was lowered by treatment of our new therapeutic approach. Therefore, this study identified the significant relationship of inhibition of tumori-sphero-genesis of PANC1ORGR with associated novel biomarkers (CD19+31+45+133+) which could be target candidates in designing drugs against pancreatic cancer. Further investigation and funding are needed to find the molecular mechanism of inhibition of tumori-sphero-genesis by this small molecule. This work was partly used the financial support from award money of 2017 Translational Research Award, Society of Toxicology and 2018 AACR Minority and Minority-Serving Institution Faculty Scholar award of Dr. Jayanta K. Das.

publication date

  • January 1, 2021

Digital Object Identifier (DOI)

start page

  • 1

end page

  • 15

volume

  • 26